EHMTI-0227. Therapeutic effectiveness of sphenopalatine ganglion (SPG) stimulation for cluster headachepathway registry study interim results at 6 months 
Background
The Pathway Registry is an open label registry of SPG stimulation therapy for cluster headache treatment. In a previous randomized, double-blind, multi-center study (Pathway CH-1 study) 68% of patients experienced clinically significant improvements.
Aim
The aim of this interim analysis is to evaluate acute and/or preventive therapeutic effectiveness at 6 months following insertion of an SPG neurostimulator.
Method
Therapeutic effectiveness (acute pain response following SPG stimulation and/or attack frequency reduction) was analyzed during the first six months following SPG neurostimulator insertion. Acute pain responders achieved relief from moderate or greater pain, or freedom from mild pain in ≥50% of analyzable attacks (with completed diary questions). Frequency responders achieved ≥50% attack frequency reduction at the six month study visit (evaluated over the previous four weeks), versus the 4 week baseline period.
Results
49 patients have been enrolled, 18 completed follow-up through six months[RJ1] (189 days post-insertion, range 149-238). Average baseline attack frequency was 28.4 attacks/week (range 0-70), and the average attack frequency at 6 months was 17.3 attacks/week (range 0-70), a 40% reduction. 67% (12/18) were responders. Of the 12 responders, 67% (N=8) were acute responders, treating 86% of their attacks effectively (N=546). 75% (N=9) were frequency responders; frequency reduced by 90% (from 22.3 at baseline to 2.1 (range 0-8) attacks/week). 5 patients were both acute and frequency responders.
Conclusion
Interim data from a registry of cluster headache patients continues to demonstrate the effectiveness of SPG stimulation therapy.
